Evidence map›Paper›PMID 27021229›Full record

ArticleThe Journal of membrane biology2016

Effects of Cisplatin Electrochemotherapy on Human Neuroblastoma Cells.

Meric Arda Esmekaya, Handan Kayhan, Alaaddin Coskun, Ayse G Canseven

Abstract read
PubMed Publisher
In one paragraph

Article in The Journal of membrane biology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Meric Arda EsmekayaDepartment of Biophysics, Faculty of Medicine, Gazi University, 06510, Beşevler, Ankara, Turkey. mericarda@yahoo.com.
Handan KayhanDepartment of Internal Medicine, Division of Hematology, Faculty of Medicine, Gazi University, Ankara, Turkey.
Alaaddin CoskunDepartment of Biophysics, Faculty of Medicine, Gazi University, 06510, Beşevler, Ankara, Turkey.
Ayse G CansevenDepartment of Biophysics, Faculty of Medicine, Gazi University, 06510, Beşevler, Ankara, Turkey.
Gazi University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Electrochemotherapy is the usage of electroporation to introduce chemotherapeutic drugs through membrane pores into target cells for cancer treatment. The effectiveness of chemotherapeutic drugs would be increased dramatically when they are used in electrochemotherapy than standard chemotherapy. In the present study, we investigated the effects of cisplatin treatment with electroporation on human SH-SY5Y neuroblastoma cells. SH-SY5Y cells were treated with different concentrations (0.15-24 µg/mL) of cisplatin and then exposed to 1500 volts per centimeter (V/cm), 100 microseconds (µs) pulse duration, and 1 Hertz (Hz) electric pulses. Cisplatin alone showed a dose-dependent effect on cell viability. On the other hand, cisplatin + electroporation treatment was more effective than cisplatin treatment alone. Lower doses of cisplatin treatment with electroporation was as effective as higher doses of cisplatin treatment without electroporation. These results indicated that cisplatin cytotoxicity was potentiated after exposure of cells to high intensity electric pulses and low doses of cisplatin can be used with electroporation in the treatment of neuroblastoma.

Indexed as

ElectroporationAntineoplastic AgentsApoptosisCell Line, TumorCell SurvivalCisplatinElectrochemotherapyFlow CytometryHumansNeuroblastomaAntineoplastic AgentsCisplatinApoptosisCell viabilityCisplatinElectroporationNeuroblastoma

Identifiers

PMID27021229
OpenAlexW2328643872

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.